Hoechst Pakistan Limited (PSX:HPL)

Market Cap	31.44B
Revenue (ttm)	28.03B
Net Income (ttm)	2.07B
Shares Out	9.64M
EPS (ttm)	215.09
PE Ratio	15.16
Forward PE	n/a
Dividend	135.00 (3.97%)
Ex-Dividend Date	Mar 26, 2025

Volume	557
Average Volume	495
Open	3,204.02
Previous Close	3,397.93
Day's Range	3,203.33 - 3,459.00
52-Week Range	1,300.04 - 3,520.88
Beta	0.22
RSI	53.44
Earnings Date	May 2, 2025

About Hoechst Pakistan

Hoechst Pakistan Limited engages in the manufacture, trading, and sale of pharmaceutical and related products in Pakistan, Afghanistan, and internationally. The company provides its allergy management, anti-diarrheals, antiemetic, antibiotic, cardiology, consumer healthcare, diabetes, and emergency care products under Flagyl, Clexane, Lantus, Amaryl, Claforan, Haemaccel, Secnidazole forte, Rulid, Targocid, Tavanic, Tarivid, Aventriax, Stemetil, Lasix, Winstor, Tritace, Cordarone, CoAprovel, Aprovel, CoPlavix, Selsun Blue, Apidra, Toujeo, Soliqu...

• Industry: Pharmaceutical Preparations
• Founded: 1967
• Employees: 837
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: HPL

Financial Performance

In 2024, Hoechst Pakistan's revenue was 26.75 billion, an increase of 25.17% compared to the previous year's 21.37 billion. Earnings were 1.86 billion, an increase of 414.72%.